

## Bibliografía

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. *Lancet*. 2016;388:2023-38.
2. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. *Nat Rev Rheumatol*. 2015;11:276-89.
3. Prince FH, Bykerk VP, Shadick NA, Lu B, Cui J, Frits M, *et al*. Sustained rheumatoid arthritis remission is uncommon in clinical practice. *Arthritis Res Ther*. 2012;14:R68.
4. Wilke T, Mueller S, Lee SC, Majer I, Heisen M. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. *BMC Musculoskelet Disord*. 2017;18:332.
5. Virkki LM, Valleala H, Takakubo Y, Vuotila J, Relas H, Komulainen R, *et al*. Outcomes of switching anti-TNF drugs in rheumatoid arthritis-a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). *Clin Rheumatol*. 2011;30:1447-54.
6. Huizinga TWJ, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, *et al*. Sarilumab, a fully human monoclonal antibody against IL-6R $\alpha$  in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. *Ann Rheum Dis*. 2014;73:1626-34.
7. Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, *et al*. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. *Arthritis Rheumatol*. 2015;67:1424-37.
8. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, *et al*. Adverse effects of biologics: a network meta-analysis and Cochrane overview. *Cochrane Database Syst Rev*. 2011;CD008794.
9. Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, *et al*. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/ intolerance to tumour necrosis factor inhibitors. *RMD Open*. 2017;3:e000416.
10. Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, *et al*. Sarilumab and Nonbiologic Disease- Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. *Arthritis Rheumatol*. 2017;69:277-90.
11. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, *et al*. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. *Nat Med*. 2011;17:1481-1489.
12. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, *et al*. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. *PLoS One*. 2010;5:e14328.
13. Qu D, Liu J, Lau CW, Huang Y. IL-6 in diabetes and cardiovascular complications. *Br J Pharmacol*. 2014;171:3595-603.
14. Ogata A, Morishima A, Hirano T, Hishitani Y, Hagihara K, Shima Y, *et al*. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. *Ann Rheum Dis*. 2011;70:1164-5.
15. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA*. 2001;286:327-34.
16. Genovese MC, Burmester RG, Hagino O, van Hoogstraten H, Mangan E, Thangavelu K, *et al*. Effect of sarilumab on glycosylated hemoglobin in patients with rheumatoid arthritis and diabetes. *Ann Rheum Dis*. 2019;78:1128-9.
17. Otsuka Y, Kiyohara C, Kashiwado Y, Sawabe T, Nagano S, Kimoto Y, *et al*. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. *PLoS One*. 2018;13:e0196368.
18. Genovese MC, Fleischmann R, Hagino O, Hu CC, Pena-Rossi C, Sadeh J, *et al*. The effect of Sarilumab in combination with dmards on fasting glucose and glycosylated hemoglobin in patients with rheumatoid arthritis with and without diabetes. [Abstract 1822]. En: 2017 ACR/ARHP Annual Meeting. *Arthritis Rheumatol*. 2017;69.
19. Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. *Rheumatology (Oxford)*. 2014;53:2143-54.
20. Castagné B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. *PLoS One*. 2019;14:e0220178.
21. Grøn KL, Arkema EV, Glinthorg B, Mehnert F, Østergaard M, Dreyer L, *et al*. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. *Ann Rheum Dis*. 2019;78:320-7.
22. Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, *et al*. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. *J Rheumatol*. 2013;40:768-80.
23. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, *et al*. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid

- arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis*. 2017;76:840-7.
24. Burmester GR, Hagino O, Dong Q, Stanislav M, Gomez-Centeno A, Selmi C, *et al*. Unique changes in hemoglobin with sarilumab versus adalimumab are independent of better disease control in patients with rheumatoid arthritis (RA). [Abstract 1528]. En: 2018 ACR/ARHP Annual Meeting. *Arthritis Rheumatol*. 2018;70.
  25. Balsa A, Lojo-Oliveira L, Alperi-López M, García-Manrique M, Ordóñez-Cañizares C, Pérez L, *et al*. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study. *Reumatol Clin*. 2019;15:102-8.
  26. Crotti C, Biggioggero M, Becciolini A, Favalli EG. Sarilumab: patient-reported outcomes in rheumatoid arthritis. *Patient Relat Outcome Meas*. 2018;9:275-84.
  27. Michelsen B, Kristianslund EK, Sexton J, Hammer HB, Fagerli KM, Lie E, *et al*. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. *Ann Rheum Dis*. 2017;76:1906-10.
  28. Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, *et al*. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. *Arthritis Res Ther*. 2016;18:198.
  29. Corominas H, Alegre C, Narváez J, Fernández-Cid CM, Torrente-Segarra V, Gómez MR, *et al*. Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab: ACT-AXIS study. *Medicine (Baltimore)*. 2019;98:e15947.
  30. Strand V, Mangan E, Hagino O, Sadeh J, Boklage S, Kimura T, *et al*. Exploring the Effects of Depressive Symptoms on the Efficacy of Sarilumab and Improvements in Health-Related Quality of Life. [Abstract 1545]. En: 2018 ACR/ARHP Annual Meeting. *Arthritis Rheumatol*. 2018;70.
  31. Gossec L, Strand V, Proudfoot C, Guillonneau S, Kimura T, van Hoogstraten H, *et al*. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. *J Rheumatol*. 2019;46:1259-67.
  32. Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, *et al*. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. *Arthritis Res Ther*. 2018;20:129.
  33. Intongkam S, Samakarnthai P, Pakchotanon R, Narongroeknawin P, Assavatanabodee P, Chaiamnuay S. Efficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and/or Biologics Therapy. *J Clin Rheumatol*. 2019;25:329-34.
  34. Gossec L, Boklage S, St John G, van Hoogstraten H, Kimura T. Arthritis Rheumatol. Pain Is Improved in Around 50% of Patients and Fatigue in 40% of Patients with Rheumatoid Arthritis Treated with Sarilumab in the Target, Mobility and Monarch Trials. [Abstract 1523]. En: 2018 ACR/ARHP Annual Meeting; 2018.
  35. Emery P, van Hoogstraten H, Jayawardena S, Mangan EK, Cejas P, Verschueren P. Efficacy of Sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab. [Abstract 2468]. En: 2017 ACR/ARHP Annual Meeting. *Arthritis Rheumatol*. 2017;69.